Investors

A public brief on the opportunity, at its current stage.

What we are building, where it stands, who is building it and what the next milestone needs. Structure, budget, runway, ownership and terms are covered in a private brief after an initial fit conversation. Nothing on this page is an offer of securities.

Thesis

Research instruments for a mechanism the field can now see but few can measure.

Over the past fifteen years, researchers have described a brain-wide clearance pathway, imaged its sleep-linked dynamics in people, and connected its decline to aging and neurodegenerative disease. How clearance is best measured, and how much it can be influenced, is still being worked out, and most of that work needs equipment only a few laboratories own.

Our thesis is that a measurement and control platform built from certified industrial components, with independent measurement and a separate safety function, can be made precise, inexpensive and reproducible enough for many laboratories to run the same experiments and check one another’s results. That is an engineering hypothesis. We will test it on the bench before we describe it as anything more.

Stage · updated October 13, 2026

Bench prototype in development. Research stage; claims of benefit follow evidence and regulatory review.

Components for the first bench configuration arrived and were inventoried in late September 2026. Assembly has begun; the prototype specification is being finalized.

Next milestone: Measurement characterization: a repeatability, calibration and timing report for stated conditions, reviewed by someone outside the program.

Structure

NeuroClearance is a research and engineering program of NuvoNexus, LLC, a company founded and led by David Sherrer. MNEOS is the institutional home that publishes the program’s milestones and open problems. The investment vehicle, intellectual-property ownership and any investor restrictions are set out in the private brief.

The opportunity, stated carefully

Six questions investors ask, answered at the level we can publish.

  1. What is the first use case?

    A bench measurement and control platform for supervised laboratory research on the physiological conditions linked to brain fluid transport. The intended operator is a research group with scientific or clinical oversight; the first experiments are non-human characterization and verification runs. NeuroClearance record

  2. Who would pay?

    Working commercial hypothesis: research instrumentation supplied to laboratories and clinical research groups, with licensing and partnerships as later options. Customer demand has not been validated, and we will not describe it as validated until collaborators are running the platform. Research hypothesis

  3. What is differentiated?

    Stated as targets, to be shown by measurement: cost low enough for many laboratories to own one; independent measurement of every controlled quantity; a safety function with its own authority to stop the system; and run logs complete enough for outside audit. The enabling mechanism is discussed privately. Research hypothesis

  4. What does capital unlock?

    The next financed milestone is measurement characterization of the first bench unit. Deliverable: a repeatability, calibration and timing report for stated conditions, reviewed by at least one outside metrology or controls specialist. Budget, runway and terms are in the private brief. NeuroClearance record

  5. Who closes the gaps?

    Founder-led, with engineering support from the NuvoNexus and MacroVation teams and outside regulatory and patent counsel. Scientific advisors have not yet been appointed; two reviewer roles are open now. See the team page. NeuroClearance record

  6. How is intellectual property handled?

    Protection is being pursued with outside patent counsel. We are glad to discuss ownership and protection privately under agreement, and we do not describe filings publicly until counsel approves the wording. NeuroClearance record

Founder history

Verified track record, kept separate from NeuroClearance results.

  • Founded Nuvotronics in 2008 to commercialize PolyStrata®, a 3D microfabrication process for RF and millimeter-wave components developed under a DARPA program, and led it through certified production. Cubic Corporation announced the acquisition on March 14, 2019, for approximately $64 million in cash plus up to $8 million in earn-outs.
  • Earlier founded Haleos and ACT MicroDevices in wafer-level optoelectronic packaging, taken through production to acquisition.
  • Named inventor on more than 100 issued and pending patents across those companies (self-reported count; inventor records available on request).
  • Led organizations holding ISO 9001 and AS9100D certifications and delivering to U.S. government agencies and defense primes.

Lullwave, kept distinct

Lullwave is a separate consumer wellness line in development under the same company. It makes general wellness claims only, shares no research or clinical claims with this program, and is presented on its own page. Whether it forms part of the same opportunity, a separate business or a future option is addressed in the private brief.

How we approach commercialization

We design for rigorous evidence, patient safety and broad access, with a sustainable commercialization model. If any legal or economic restriction applies to an investment, it is stated precisely in the private brief rather than implied here.

Request the private brief

One email starts it.

Send a short note with your name, firm, the stage you typically invest at and what you would want to see first. David Sherrer replies personally. Investor inquiries go to this address directly, not into a general research intake.

Request the investor brief

If the button does not open your mail client, write to [email protected] with the subject “Investor brief request”.

What the private brief contains

  • Entity structure, investment vehicle and intellectual-property ownership
  • Budget and runway for the next milestone, and the milestones after it
  • Commercial assumptions and how we intend to test them
  • Technical evidence to date, under agreement and with the founder’s approval
  • Financing status and terms

Nothing on this site is an offer of securities. Investment discussions are held privately with qualified investors under separate documentation.